LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Accueil・Liste d'Actions・Puma Biotechnology Inc

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

6.94 -1.98

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.8100000000000005

Max

7.29

Chiffres clés
By Trading Economics
Revenu	3M 12M
Ventes	21M 76M
P/E Moyenne du Secteur	12.344 49.8
Marge bénéficiaire	15.633
Employés	179
EBITDA	13M 27M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-29.97% downside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	25M 383M
Ouverture précédente	8.92
Clôture précédente	6.94

Sentiment de l'Actualité

By Acuity

50%

175 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

3.07 / 3.075 Support & Résistance

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Résultats

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Résultats

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Acquisitions, Fusions, Rachats

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Résultats

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Résultats

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Résultats

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Résultats

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Résultats

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Actions en Tendance

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Résultats

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-29.97% baisse

Prévisions sur 12 Mois

Moyen 5 USD -29.97%

Haut 5 USD

Bas 5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

175 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.